aTyr Pharma (NASDAQ: LIFE) announced that it has selected an Investigational New Drug (IND) Candidate based on an immuno-modulatory and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process Development and for Potential Treatment of Severe Lung DiseasesNovember 11, 2015 7:30 AM Form 10-Q aTYR PHARMA INC For: Sep 30November 10, 2015 4:41 PM Form 8-K aTYR PHARMA INC For: Nov 10November 10, 2015 4:26 PM aTyr Pharma Announces Third Quarter 2015 Operating ResultsNovember 10, 2015 4:15 PM